Emerging treatments and signaling pathway inhibitors.

Abstract

A number of therapies that target components of the Hedgehog signaling pathway currently are in clinical trials. The specific molecules that seem most promising in basal cell carcinoma and a number of other cancers are those that target the Smoothened transmembrane protein. The pivotal phase II trials have been completed on the Smoothened inhibitor known as GDC-0449; five other agents (BMS-833923, LDE225, LEQ506, IPI926, and TAK-441) have also shown promise in animal studies and early clinical trials and have shown some efficacy in a variety of cancers that are affected by the Hedgehog signaling pathway.

• Authors: Jean Y Tang, Ashfaq A Marghoob
• Journal: Seminars in cutaneous medicine and surgery (Semin Cutan Med Surg) Vol. 30 Issue 4 Suppl Pg. S14-8 (Dec 2011) ISSN: 1558-0768 [Electronic] United States
• PMID: 22177102 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Aminoquinolines
• Anilides
• Antineoplastic Agents
• BMS-833923
• Benzamides
• Hedgehog Proteins
• HhAntag691
• Pyridines
• Quinazolines
• Retinoids
• Viral Proteins
• endonuclease V, phage T4
• Deoxyribonuclease (Pyrimidine Dimer)
• Imiquimod
• Fluorouracil

Topics

• Aminoquinolines (therapeutic use)
• Anilides (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Basal Cell Nevus Syndrome (drug therapy, metabolism, prevention & control)
• Benzamides (therapeutic use)
• Carcinoma, Basal Cell (drug therapy, metabolism, prevention & control)
• Deoxyribonuclease (Pyrimidine Dimer) (therapeutic use)
• Fluorouracil (therapeutic use)
• Hedgehog Proteins (antagonists & inhibitors)
• Humans
• Imiquimod
• Photochemotherapy
• Pyridines (therapeutic use)
• Quinazolines (therapeutic use)
• Retinoids (therapeutic use)
• Secondary Prevention
• Signal Transduction (drug effects)
• Skin Neoplasms (drug therapy, metabolism, prevention & control)
• Viral Proteins (therapeutic use)